Migraine Drugs Market by Therapeutic Classes (Triptans, Ditans, NSAIDs, Acetylcholine Inhibitors/ neurotoxins, Ergot Alkaloids, CGRP small molecule antagonists, CGRP monoclonal antibodies, and Others), Treatments (acute/abortive treatment and preventive/ prophylactic treatment), Routes of Administration (Oral, Injectable, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global migraine drugs market size is anticipated to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the high unmet needs, increased adoption of novel drug classes, and launch of Calcitonin gene-related peptide (CGRP)-based therapies.
 

Migraine is a common neurological disease which causes severe headache along with nausea, vomiting and disturbed vision. The headache last from four hours to three days also, it starts from one side of head and travel around the other side in migraine disease. The pain in migraine is related to the increased sensitivity to sound (phonophobia), sweating, increased sensitivity to light (photophobia), diarrhea, and tingling or numbness in the extremities or legs. There is no permanent cure for migraines. Migraine is commonly found in women as compared to men. Each year around 17.2% women were diagnosed with migraine and only 6.1% men were reported an attack of migraine. Treatment for migraine is targeting the prevention of full blown attack and alleviation of symptoms. The symptoms are relieved by various drugs present in the market.

Many drugs which are present in the market are accepted for acute form of condition, and headed by generic triptans as the first-line treatment. Market trend is shifting with respect to research and development by introducing CGRP-based therapy and rise in novel drug classes such as gepants, ditans, and reformulation of triptans for both chronic and episodic migraine. Hormonal medications such as hormone replacement and oral contraceptives are worsen migraine in women. Hence, globally, rise in female population is projected to aid the market in the coming years.

Migraine ranks 19^th most common reason of disability in the World Health Organization’s disability rating. As compare to other people, migraine sufferers visit doctors and emergency rooms more often and consumes twice the amount of prescription drugs. These sufferers spent more money on their healthcare segment. Therefore, rising prevalence of migraine allows more use of therapeutics for getting relief from migraine.

Market Trends, Drivers, Restraints, and Opportunities

• Growing prevalence of migraines and increasing female population are expected to drive the market growth over the forecast period.
• Increase in expenditure of research and development, high unmet needs, and rising number of pipeline of products are factors responsible for propelling the growth of the market.
• Rise in demand of quality drugs, high alcohol consumption, increase in spending on healthcare, and increasing work pressure are projected to fuel the market growth.
• Increasing awareness of migraine and its treatment options among people is anticipated to boost the expansion of the market in the coming years.
• Lack of proper diagnosis, several undiagnosed cases, and increasing generic penetration are anticipated to hamper the expansion of the market in the coming years.
• Side effects of drugs and rising preference of alternative therapies are expected to hinder the market growth over the forecast period.

Scope of the Report

The report on the global migraine drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Market Segment Insights

Triptans segment is projected to hold a major market share
In terms of therapeutic classes, the migraine drugs market is segmented into triptans, ditans, NSAIDs, acetylcholine inhibitors/ neurotoxins, ergot alkaloids, CGRP small molecule antagonists, CGRP monoclonal antibodies, and others. The triptans segment is expected to hold a key share of the market during the forecast period. It is new class of drug which upsurge level of serotonin in the brain, which decreases inflammation and constrict blood vessels. Triptans are more migraine-specific as compared to earlier ergotamines. Some of the triptans are eletriptan (Relpax), sumatriptan (Imitrex), naratriptan (Amerge), almotriptan (Axert), rizatriptan (Maxalt, Maxalt-MLT), sumatriptan and naproxen (Treximet), frovatriptan (Frova), and zolmitriptan (Zomig).

A single tablet of combination of sumatriptan and naproxen sodium (Treximet) is more effective in relieving migraine symptoms. But, there are some side effects of triptans such as drowsiness, nausea, muscle weakness, reactions at the injection site, and dizziness. Hence, triptans are not prescribed to the people who are at risk of heart attacks and strokes.

Preventive/prophylactic treatment segment is expected to grow at a rapid pace
On the basis of treatments, the market is bifurcated into acute/abortive treatment and preventive/ prophylactic treatment. The acute/abortive treatment segment is expected to account for a key share of the market in the coming years. Acute treatment comprise of therapeutic classes such as NSAIDs, triptans, ergot alkaloids, and other non-specific drugs which are prescribed over-the-counter (OTC) including aspirin, acetaminophen, and ibuprofen.

However, the preventive/ prophylactic treatment segment is anticipated to expand at a rapid pace during the forecast period owing to the approval of CGRP monoclonal antibodies. Preventive treatment includes prescription of off-label and generic medications consisting of beta-blockers such as atenolol and propranolol, divalproex sodium, and anti-epileptics such as topiramate. Presently, Teva’s Ajovy (CGRP mAb), Allergan’s Botox (neurotoxin), and Amgen/ Novartis’s Aimovig are some drugs which are approved for prevention of migraine. Still, Botox needs more than 30 injections in forehead, shoulders, and neck and does not give relief from episodic migraine. Researchers are currently focusing on usage of novel tools of actions such as corticotrophin receptor antagonism, CGRP-based receptor and ligand inhibition, and nitrous oxide inhibition.

Oral segment is expected to expand at a robust pace
Based on routes of administration, the migraine drugs market is divided into oral, injectable, and others. The injectable segment is expected to hold a key share of the market in the coming years. However, the oral segment is anticipated to expand at a rapid pace during the forecast period owing to high adoption of drugs.
 

North America is expected to dominate the market
On the basis of regions, the migraine drugs market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to high prevalence and launch of CGRP based therapies. Moreover, large target population in the U.S and increasing adoption of novel therapeutics are expected to drive the regional market growth. In the U.S. more than 37 million people were affected.

On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. Increasing awareness about disease among people, huge underserved patient population, increasing healthcare expenditure, and low-cost of production of drugs are fuelling the regional market.
 

Segments

Segments Covered in the Report
The global migraine drugs market has been segmented on the basis of

Therapeutic Classes

• Triptans
• Acetylcholine Inhibitors/ neurotoxins
• Ergot Alkaloids
• NSAIDs
• Ditans
• CGRP small molecule antagonists
• CGRP monoclonal antibodies
• Others

Treatments

• Acute / Abortive Treatment
• Preventive/ Prophylactic Treatment

Routes of Administration

• Oral
• Injectable
• Others

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Pfizer
• GlaxoSmithKline
• Allergan
• Amgen
• Eli Lilly
• Teva Pharma
• Biohaven Pharma
• Bausch Health
• Johnson & Johnson
• Valeant Pharma
• Abbott Laboratories
• AstraZeneca
• Eisai Co., Ltd.
• Endo International Plc.
• Impax Laboratories
• Merck & Co.
• Novartis International AG
• Sanofi SA

Competitive Landscape

Key players competing in the migraine drugs market are Pfizer, GlaxoSmithKline, Allergan, Amgen, Eli Lilly, Teva Pharma, Biohaven Pharma, Bausch Health, Johnson & Johnson, Valeant Pharma, Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Endo International Plc., Impax Laboratories, Merck & Co., Novartis International AG, and Sanofi SA. Major market players are adopting several business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.